CEFUROXIME FOR INJECTION, USP POWDER FOR SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
17-04-2020

Aktīvā sastāvdaļa:

CEFUROXIME (CEFUROXIME SODIUM)

Pieejams no:

FRESENIUS KABI CANADA LTD

ATĶ kods:

J01DC02

SNN (starptautisko nepatentēto nosaukumu):

CEFUROXIME

Deva:

7.5G

Zāļu forma:

POWDER FOR SOLUTION

Kompozīcija:

CEFUROXIME (CEFUROXIME SODIUM) 7.5G

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

100ML

Receptes veids:

Prescription

Ārstniecības joma:

SECOND GENERATION CEPHALOSPORINS

Produktu pārskats:

Active ingredient group (AIG) number: 0122448003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2006-10-05

Produkta apraksts

                                Cefuroxime for Injection, USP – Product Monograph Page 1 of 36_ _
PRODUCT MONOGRAPH
PR CEFUROXIME FOR INJECTION, USP
750 mg / 15 mL vials
1.5 g / 50 mL vials
7.5 g / 100 mL Pharmacy Bulk Package Vial
Antibiotic
FRESENIUS KABI CANADA LTD.
Date of Preparation:
165 Galaxy Blvd, Suite 100
April 17, 2020
Toronto, ON M9W 0C8
Control No.: 233970
Cefuroxime for Injection, USP – Product Monograph
Page 2 of 36
PRODUCT MONOGRAPH
PR
CEFUROXIME FOR INJECTION, USP
750 mg / 15 mL vials
1.5 g / 50 mL vials
7.5 g / 100 mL Pharmacy Bulk Package Vial
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION AND CLINICAL PHARMACOLOGY
_In vitro_ studies demonstrate that the bactericidal action of
cefuroxime results from inhibition of
bacterial cell wall synthesis by inhibiting the transpeptidase and
carboxypeptidase enzymes.
INDICATIONS AND CLINICAL USES
TREATMENT
Cefuroxime for Injection, USP may be indicated for the treatment of
patients with infections
caused by susceptible strains of the designated organisms in the
following diseases:
LOWER RESPIRATORY TRACT INFECTIONS:
Pneumonia caused by _Streptococcus pneumoniae, Haemophilus influenzae_
including ampicillin-
resistant strains, _Klebsiella_ species, _Staphylococcus_ _aureus_
including ampicillin-resistant (but not
methicillin-resistant) strains, _Streptococcus_ _pyogenes_, and
_Escherichia coli. _
URINARY TRACT INFECTIONS:
Caused by _Escherichia coli_, and _Klebsiella _species.
SOFT TISSUE INFECTIONS:
Caused by _Staphylococcus aureus, _including ampicillin-resistant (but
not methicillin-resistant)
strains, _Streptococcus pyogenes, Escherichia coli_, and_ Klebsiella_
species.
MENINGITIS:
Caused by _Staphylococcus_ _aureus_ including ampicillin-resistant
(but not methicillin-resistant)
strains, _Streptococcus pneumoniae, Haemophilus influenzae_, and
_Neisseria_ _meningitidis_.
GONORRHEA:
Caused by _Neisseria_ _gonorrhoeae_ including ampicillin-resistant
strains.
Cefuroxime for Injection, USP – Product Monograph
Page 3 of 36
BONE AND JOINT INFECTIONS:
Caused by _Staphylococcus aureus_ (p
                                
                                Izlasiet visu dokumentu
                                
                            

Dokumenti citās valodās

Produkta apraksts Produkta apraksts franču 17-04-2020

Meklēt brīdinājumus, kas saistīti ar šo produktu